Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Moderate Buy” by Brokerages

Oculis Holding AG (NASDAQ:OCS) has been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $38.3333.

A number of research analysts recently commented on the company. Robert W. Baird decreased their price objective on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. Needham & Company LLC cut their target price on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Guggenheim reduced their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. JPMorgan Chase & Co. decreased their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st.

Oculis Price Performance

Oculis stock opened at $14.12 on Friday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $20.49 and a 200 day moving average price of $23.86. Oculis has a 12-month low of $10.52 and a 12-month high of $34.47. The stock has a market cap of $818.68 million, a P/E ratio of -6.63 and a beta of 0.44.

Oculis (NASDAQ:OCS) last posted its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. Sell-side analysts anticipate that Oculis will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Gildi lifeyrissjodur acquired a new stake in shares of Oculis during the fourth quarter valued at about $50,250,000. Aberdeen Group plc lifted its holdings in shares of Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after acquiring an additional 493,827 shares during the last quarter. SR One Capital Management LP lifted its holdings in shares of Oculis by 98.8% in the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after acquiring an additional 318,522 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Oculis during the 4th quarter worth approximately $9,862,000. Finally, Alyeska Investment Group L.P. boosted its position in shares of Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after purchasing an additional 200,000 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.